1Gautam A, Li ZR, Bepler G. RRMl-induced metastasis suppression through PTEN-regulated pathways[J]. Oncogene, 2003, 22(14) :2135-2142.
2Rha SY, Jeung HC, Choi YH, et al. An association betweenRRM1 haplotype and gemcitabine- induced neutropenia in breast cancer patients[J]. Oncologist, 2007,12 ( 6 ), 622-630.
3Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines[J]. Cancer Res,2004,64 (11):3761-3766.
4Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitahine[J]. Ann Oncol,2006,17(12) : 1818-1825.
6Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets,and side effects[J].N Engl J Med,2003,348(6): 538-549.
7Bergman AM, Eijk PP, Ruiz van Haperen VW, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant[J]. Cancer Res,2005,6(20) : 9510-9516.
8Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage I1 13-HI A- B non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery[J]. Clin Cancer Res, 2004, 10 (12 Pt 2) : 4215s-4219s.
2Goan YG,Zhou B,Hu E,Mi S,et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxy -cytidine in the human KB cancer cell line. Cancer Res, 1999,59, 4204.
3Kurbacher CM ,Cree IA ,Bruckner HW,et al . Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs ,1998,9(1):51.
4Dumontet C ,Fabianowska-Majewsda K ,Mantincic D ,et al.Common resistance mechanisms to deoxynucleoside analogues in variants of the hum an erythroleukaemic line K562.Br J Haematol,1999, 106(1): 78.
5DavidsonJ D,M aL ,Flagela M ,et al.An increase in the expression of ribonucleotide reductase large subunitl is associated with gemcitabine resistance in non-small cell lung cancer cell lines.Cancer Res ,2004,64(11):3761.
6Bunn P,Lynch TJ,Ettinger TS,et al.Lung Cancer,CCO Independent Conference Coverage of the 2005 Annual Meeting of the ASCO[DB/OL].Clinical Care Options,
7Rosell R,Danenberg KD,Alberola V,et al.Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients[J].Clin Cancer Res,2004,10:1318-1325.
8Rosell R,Felip E,Taron M,et al.Gene expression as a predictive marker of outcome in stage ⅡB-ⅢA-ⅢB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery[J].Clin Cancer Res,2004,10(suppl 12):S4215-S4219.
9Rosell R,Cobo M,Isla D,et al.ERCC1 mRNA-based randomized phase Ⅲ trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage Ⅳ non-smallcell lung cnncer (NSCLC) patients (p)[J].J Clin Oncol,2005,23(suppl 1):7002.
